FaF:FABU1_15 Biopharmaceuticals - Informace o předmětu
FABU1_15 Biopharmaceuticals
Farmaceutická fakultapodzim 2022
- Rozsah
- 1/0/0. 2 kr. Ukončení: zk.
- Vyučující
- doc. PharmDr. Oldřich Farsa, Ph.D. (přednášející)
doc. PharmDr. Aleš Franc, Ph.D. (přednášející) - Garance
- doc. PharmDr. Oldřich Farsa, Ph.D.
Ústav chemických léčiv – Ústavy – Farmaceutická fakulta - Rozvrh
- každý sudý čtvrtek 8:00–9:40 44-247
- Předpoklady
- FAKULTA(FaF) || OBOR(MUSFaF)
- Omezení zápisu do předmětu
- Předmět je určen pouze studentům mateřských oborů.
- Mateřské obory/plány
- Multidisciplinární studia na farmaceutické fakultě (program CST, KOS)
- Pharmacy (program FaF, M-FARMA)
- Cíle předmětu
- Biotherapeutics ("or biological and biotechnological substances" in WHO terms) are medicines with a relative molecular mass in most greater than 1 000 (in contrast to classical "chemical" medicines called "small molecules"). They are usually produced in other ways than by common chemical synthesis (recombinant technologies are typical). They mostly have neither exactly defined chemical structure nor exactly known relative molecular mass because they are often mixtures of structurally related biopolymers. They frequently exhibit primary structure (monomers' sequence, eg. that of amino acids, nucleotides, or monosaccharides) and secondary, tertiary, and quarternary one. This group includes eg. monoclonal antibodies, modified receptor molecules, protein and peptide hormones, cytokines, hematopoietic factors, modified oligonucleotides, vaccines of all generations, and heparins. Biologic therapy grows rapidly during the past decades and is often considered to be the last chance in the treatment of cancer or autoimmune diseases. The wider usage of biotherapeutics is still slowed down by their high price. This problem is, however, being a step wisely overcome by the introduction of biosimilar products which mean an analogy of generics in terms of small molecules.
- Výstupy z učení
- A student will, after passing the subject, be capable to enumerate main groups of biologic drugs; their main structural characteristics; their general mechanisms of activity; at least 5 examples of drugs in use or development from every structural group.
- Osnova
- Content of the discipline expressed as topics of lectures:
Biological therapeutics (biologics) and conventional small molecule drugs - definition, history, contemporary situation, classification of biologics, fundamentals of their terminology. (Farsa)
Modified receptor molecules as therapeutics.(Farsa)
Drugs with peptide structure (except enzymes and antibodies). (Farsa)
Antisense oligonucleotides. Poly- and oligosaccharides as drugs. (Farsa)
Therapeutic monoclonal antibodies. (Farsa)
Enzymes as drugs. (Farsa)
Classical and modern vaccines. (Franc).
- Content of the discipline expressed as topics of lectures:
- Literatura
- doporučená literatura
- U.S. Department of Health and Human Services Food and Drug Admin. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD, USA, 2015.
- Ministry of Health, Labour and Welfare of Japan. The Japanese Pharmacopoeia. 17th Edition, English version. Tokio, 2016.
- WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva, 2013.
- WHO. World Health Organization: International Nonproprietary Names (INN) for biological and biotechnological substances (a review), WHO/EMP/RHT/TSN/2016.1. Geneva, 2016.
- Ng Rick. Drugs: From Discovery to Approval. Second Edition. 2009. ISBN 978-0-470403587. URL info
- Výukové metody
- Lectures
- Metody hodnocení
- A grade. A written quiz.
- Vyučovací jazyk
- Angličtina
- Další komentáře
- Studijní materiály
Předmět je dovoleno ukončit i mimo zkouškové období.
- Statistika zápisu (podzim 2022, nejnovější)
- Permalink: https://is.muni.cz/predmet/pharm/podzim2022/FABU1_15